{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:22:24Z","timestamp":1783948944218,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p>In 2005, incobotulinumtoxinA (Xeomin<jats:sup>\u00ae<\/jats:sup>), a new botulinum toxin (BT) type A drug without complexing proteins (CPs), became available. This paper reviews the specific features of Xeomin<jats:sup>\u00ae<\/jats:sup> and the experience gathered with it during the last 5\u2003years. Compared with conventional BT drugs, Xeomin<jats:sup>\u00ae<\/jats:sup>\u2019s extended shelf live and its simplified temperature restrictions indicate that CPs are not necessary for BT drug stability. Its reduced molecular size does not translate into diffusion differences, and its potency labelling is identical to that of onabotulinumtoxinA (Botox<jats:sup>\u00ae<\/jats:sup>). With a reduced content of inactivated botulinum neurotoxin, Xeomin<jats:sup>\u00ae<\/jats:sup> should have reduced antigenicity. Lack of CP\u2019s may further reduce antigenicity. Xeomin<jats:sup>\u00ae<\/jats:sup>\u2019s therapeutic efficacy against cervical dystonia, blepharospasm and spasticity has been proven in large randomised, double\u2010blind and placebo\u2010controlled studies leading to registrations in many countries. Additional successful clinical use in axillary hyperhidrosis, hemifacial spasm, re\u2010innervation synkinesias and hypersalivation as well as in dystonia and spasticity in extended doses and throughout extended observation periods has been documented meanwhile. Lack of reported cases of antibody\u2010induced therapy failure (ABF), as to date, support the hypothesis of an improved antigenicity.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2011.03559.x","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T12:07:13Z","timestamp":1319803633000},"page":"385-389","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Five\u2010year experience with incobotulinumtoxinA (Xeomin<sup>\u00ae<\/sup>): the first botulinum toxin drug free of complexing proteins"],"prefix":"10.1111","volume":"19","author":[{"given":"D.","family":"Dressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511575761"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32833c3405"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.64.5.1589-1594.1996"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S14902"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M703446200"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.16.1.107-109.1977"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.6.2420-2425.1998"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(01)00157-X"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvj161"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.021246-0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2008.04.038"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163767.99354.C3"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0323-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02877.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2008.04.030"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2010.12.019"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000240951.18821.50"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21343"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6580"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.28421-0"},{"key":"e_1_2_6_22_2","first-page":"357","article-title":"Immunological properties of Hn\u201033 purified from type A Clostridium botulinum","volume":"9","author":"Sharma SK","year":"2000","journal-title":"J Nat Toxins"},{"issue":"1","key":"e_1_2_6_23_2","first-page":"S15","article-title":"Immunogenicity of NT201 (Xeomin\u00ae) in Cynomolgus monkeys following high\u2010dose injections","volume":"23","author":"Eisele K\u2010H","year":"2008","journal-title":"Mov Disord"},{"key":"e_1_2_6_24_2","first-page":"238","article-title":"Comparative antigenicity of three preparations of botulinum neurotoxin A in the rabbit","volume":"9","author":"Blumel J","year":"2006","journal-title":"Neurotox Res"},{"issue":"2","key":"e_1_2_6_25_2","first-page":"S67","article-title":"Botulinum toxin therapy failure: causes, evaluation procedures and management strategies","volume":"4","author":"Dressler D","year":"1997","journal-title":"Eur J Neurol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22157"},{"issue":"2","key":"e_1_2_6_27_2","first-page":"51","article-title":"Botulinum toxin therapy: risk factors for therapy failure","volume":"15","author":"Dressler D","year":"2000","journal-title":"Mov Disord"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-006-2090-2"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055087.96356.BB"},{"key":"e_1_2_6_30_2","unstructured":"PickettA PanjwaniN O\u2019KeeffeRS.Potency of Type A Botulinum Toxin preparations in clinical use. 40th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC) Nov. 2003 Atlanta USA."},{"issue":"5","key":"e_1_2_6_31_2","first-page":"S22","article-title":"The biochemistry of botulinum toxin type B","volume":"55","author":"Setler P","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081463"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050345"},{"issue":"2","key":"e_1_2_6_34_2","first-page":"S227","article-title":"Antigenicity differences between botulinum toxin drugs","volume":"25","author":"Adib Saberi F","year":"2010","journal-title":"Mov Disord"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7583"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181692735"},{"issue":"1","key":"e_1_2_6_37_2","first-page":"S20","article-title":"Equivalent potency of Xeomin\u00ae and Botox\u00ae","volume":"23","author":"Dressler D","year":"2008","journal-title":"Mov Disord"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-010-0529-x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181b13308"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-010-0372-0"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2011.03559.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2011.03559.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1468-1331.2011.03559.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2011.03559.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:49:39Z","timestamp":1693356579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2011.03559.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1468-1331.2011.03559.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03559.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"2011-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}